deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00642642

Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

A Phase II/III Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Isolagen Therapy in the Treatment of Moderate to Sever Facial Acne Scarring

Sponsor: Castle Creek Biosciences, LLC.

Conditions Acne Scarring of the Face
Interventions Autologous Human Fibroblasts (azficel-T) Placebo
Updated 7 times since 2017 Last updated: Jul 19, 2013 Started: Nov 30, 2007 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Acne Scarring of the Face and is currently completed. Castle Creek Biosciences, LLC. leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotCompleted~Feb 2021 – ~Jul 2024 · 41 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Feb 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Castle Creek Biosciences, LLC.
Data source: Castle Creek Biosciences, LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations